For the twelve months ended Sep 30, 2026, Biote Corp. reported $178.91M of revenue and -$2.39M of net income.
BTMD revenueQ3 2026$43.33M
- Quarter YoY
- -9.6%
- QoQ
- -2.0%
- FY YoY
- -2.5%
BTMD revenue was $43.33M in fiscal Q3 2026 (ended Sep 30, 2026), down 9.6% from a year earlier and down 2.0% from the prior quarter. For the full fiscal 2025 it was $192.22M, down 2.5% from fiscal 2024. It rose in 3 of the last 4 fiscal years.
BTMD net incomeQ3 2026$407.0K
- Quarter YoY
- -95.0%
- FY YoY
- +756.7%
BTMD net income was $407.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 95.0% from a year earlier. For the full fiscal 2025 it was $27.05M, up 756.7% from fiscal 2024.
BTMD EPSQ3 2026$0.01
- Quarter YoY
- -95.5%
- FY YoY
- +722.2%
BTMD diluted EPS was $0.01 in fiscal Q3 2026 (ended Sep 30, 2026), down 95.5% from a year earlier. For the full fiscal 2025 it was $0.74, up 722.2% from fiscal 2024.
BTMD free cash flowQ3 2026$1.11M
- Quarter YoY
- -91.8%
- FY YoY
- -22.2%
BTMD free cash flow was $1.11M in fiscal Q3 2026 (ended Sep 30, 2026), down 91.8% from a year earlier. For the full fiscal 2025 it was $30.18M, down 22.2% from fiscal 2024.
Source: XBRL data Biote Corp. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.